Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IHV01
- Development stage
- Phase 1
- Lead developer
- Institute of Human Virology
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
IHV01 is a protein subunit HIV-1 vaccine candidate composed of a full-length single chain (FLSC) gp120-CD4 chimeric protein formulated with an aluminum phosphate adjuvant. The FLSC construct presents a highly conserved CD4-induced (CD4i) HIV-1 envelope structure designed to elicit cross-reactive humoral immune responses against diverse HIV-1 strains. The vaccine aims to induce broadly reactive antibodies targeting multiple domains of the HIV envelope, including conserved CD4i epitopes on gp120. IHV01 has been evaluated in phase 1 clinical trials for safety and immunogenicity in healthy, HIV-uninfected adults and was found to be safe, well tolerated, and capable of inducing robust antibody responses[1][3][6]. It is being developed primarily as a preventive vaccine for HIV-1 infection.
- Other names
- Full-Length Single Chain gp120-CD4 chimeric subunit vaccineFLSC vaccine
02
Targets
Env (HIV-1 envelope glycoprotein)gp120 (HIV-1 envelope glycoprotein (gp120/gp41) epitopes)
Beyond the preview
Go deeper on IHV01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IHV01.